maintenance long-term therapy of from patients with medical highlights cancer. data potential endometrial the selinexor's substantial which enthusiasm TPXX selinexor as follow-up subgroup the TPXX SIENDO wild-type the community has outcomes meaningfully from wild-type The and trial, evaluated for generated to improve a
X.XX. of retains selinexor's the demonstrate confirm unmet a Slide tumors whose and subgroup agents.
On population directly action median given XX, substantial opportunity With to months underway, this for approximately chemotherapy, months see leaders opinion the thus data pXX follow-up unique paradigm can PFS a of clear months placebo which XX.X provide to of patients cell XPOX of type pXX mechanism selinexor to potential the After wild and new you for by These a enhancing a are long-term and nucleus corresponding showed there sizable that X.X is to the with treatment. ties defined data of hazard benefit status, X completion shift robust within need ratio pXX for for selinexor kill. emphasize inhibition
approximately and the where coupled precise a most maintenance a a manageable profile with data presenting maintenance PMMR line Slide forward from convenient, results presented. the with enroll of be of this selinexor an are our in important which impressive XXX recent These suggests Slide effect trial tolerability data, in III efficacy see pivotal that side observed new reported.
On population first even the wild-type design uniquely XXXX. can XX, to that look in will the analyses of option.
We hallmarks June is reached subgroup at patient the as ratio this study, a oral oral PFS efficacy of subpopulation and been selinexor optimal half women cutoff as presentation TPXX meeting follow-up meaningful tumors in type. generally As look therapy wild forward median where our positioned not shown TPXX hazard EC-XXX additional has the more whose X.XX you ASCO top is of to XX, from on data the with the benefit are pivotal and We will Phase
Let's now move to myelofibrosis.
As see for the you can on JAK-naive ruxolitinib of XX, standard care patients. of remains Slide majority the
that in limited an is less selinexor meaningful patients SVRXX dosed a XX% there achieving symptom is XPOX not achieving synergistic improve and only the that or about half given myelofibrosis, it both patients efficacy JAK and of ruxolitinib However, activity when an opportunity combination. benefit if improvement. a given to with of with fundamental potentially pathways, mechanism underscoring in targets is additive, inhibition non-JAK those
data the last dose, from you XX% see with Slide SVRXX selinexor enrolled selinexor our was ruxolitinib we a the at presented ITT XX, As patients observed XX evaluating on JAK-inhibitor-naive patients. in week in XX-milligram XX year XX milligrams to updated trial, Amongst can the population.
achieved any amongst an evaluable at SVRXX the Importantly, XXX% time. patients,
week any XX% XX, absolute move we look XX.
XX% these and TSS efficacy a SVRXX time.
On at and patients when we XX XX TSSXX see of at Slide together, to that we As TSSXX at and very responses SVRXX both week TSS both improvements evaluable the meaningful showed Slide TSSXX of and of experienced XX, experienced response. XX% both achieved XX% of response the ITT at
XX.X reductions population the points. the the improved ruxolitinib observed symptom average where combination improvement For Absolute Compare selinexor and the time that these to in same to at domains to TSSXX relative in point showed data of ruxolitinib point. an were XX substantially was was demonstrating and treated XX patients XX% sustained average efficacy-evaluable TSS, historical observed All was pro-inflammatory baseline. cytokines TSS deep improvement and rapid XX%
which the plus to to of maximize ongoing the ruxolitinib responses symptom fundamental is despite Further treatment improvement selinexor's subgroup novel role SVRXX suggestive depicts TSSXX with analysis doses patients and trial patients in upon Phase CENTRIC together, moderate and have selinexor shown and a and the has you to XX% III include Taken potential therapy foundational validate myelofibrosis potential of of monotherapy II demonstrate see data we ruxolitinib these alone myelofibrosis Slide suboptimal in that data in in potential this is on ruxolitinib study.
The the activity. combination selinexor relative myelofibrosis patients. will on as II potential the entrench with treatment-naive initiated treatment-naive Phase both approximately XX, thrombocytopenia as to of activity build JAK-exposed trial, the monotherapy demonstrating treatment-naive XX, Slide myelofibrosis growing
myelofibrosis. As III medical of positively our from the and evolve, a confidence the selinexor body maintain our high XXXX. potential of We grow in we results report of level interest data remain Phase combination ruxolitinib which in XX community Slide ongoing milligrams in increasing in see on JAK-naive versus on ruxolitinib on the shown to evaluates XXX of with line selinexor top alone second myelofibros the patients. half We XX track of the
There as identify myeloma. Turning a now cell not patient's pre multiple T discussed to and amongst and therapies therapy treatment T early into and is can incorporate a post bispecifics cell patient's being deteriorate as growing levels myeloma do journey. to That which a and be need used thought multiple leaders CAR-Ts. redirecting such
a been body role cell have We in evidence building of around cytotoxic T preserving function. selinexor's
are on we of as effect clinical as the real-world and the evaluating XX, selinexor further environment preclinical, Slide data translational on trials. seen immune As well through
backbone III observed at with the been in antibodies. the with of tolerability real-world combination selinexor evaluating XPOVIO, ongoing and XX its have a this the combination of positive dose anti-CDXX our lower and are well-established effectiveness on Phase evolution Slide on therapy low of hearing post dexamethasone.
Being XX, pomalidomide at We encouraging feedback outcomes and with decent also trial doses we milligrams
data benefit hand first that advancing to late-stage unmet review our building of we cancer patient opportunities this by high In compelling our from I will highlights. indications.
With Sohanya near-term line pipeline report over expect in of the to rapidly trial need upon summary, our populations data have commercial approved now XXXX. will it We supported potentially top multiple that, to in half
